PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980617
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980617
The global colorectal cancer (CRC) screening market was valued at USD 18.62 billion in 2025 and is projected to grow to USD 19.42 billion in 2026, reaching USD 27.69 billion by 2034, exhibiting a CAGR of 4.50% during the forecast period. North America dominated the market in 2025 with a 65.04% share, driven by high awareness, early detection programs, and favorable reimbursement policies. CRC primarily affects adults aged 45 and above, with early detection significantly improving treatment outcomes. The rising prevalence of colorectal cancer and government initiatives promoting screening are key drivers fueling market growth.
Market Drivers
The increasing incidence of colorectal cancer is a major market driver. Developed countries report higher incidence rates, while middle- and low-income countries are witnessing rising cases due to unhealthy lifestyles and aging populations. According to the American Cancer Society in 2025, rectal cancer and colon cancer cases in the U.S. were 46,950 and 107,320, respectively. Furthermore, the Centers for Disease Control and Prevention (CDC) reported 147,931 new colorectal cancer cases in the U.S. in 2022, with 53,779 deaths in 2023. This rising incidence and mortality have heightened the demand for CRC detection and are expected to propel market growth.
Market Restraints
Despite strong clinical rationale, the market faces significant restraints. Low screening participation, especially in low- and middle-income countries, limits adoption. Even in developed regions, fear, discomfort, and lack of awareness reduce screening uptake. Colonoscopy, the gold standard, is invasive, requires bowel preparation, sedation, and specialized infrastructure, driving up per-test costs. Emerging modalities like stool-DNA and blood-based tests are expensive compared to fecal immunochemical tests (FIT), restricting access and limiting public program inclusion. Reimbursement variability also contributes to uneven access globally.
Market Opportunities
Non-invasive and at-home CRC screening tests are emerging as substantial opportunities. These tests, such as FIT, fecal occult blood tests (FOBT), and multi-target stool DNA tests, eliminate procedural risks, bowel preparation, and discomfort, enhancing adoption among asymptomatic and screening-averse populations. In July 2024, Guardant Health received FDA approval for its Shield blood test as the first primary screening option for adults aged 45 and above, supporting Medicare reimbursement. Collaborations among diagnostics companies, healthcare providers, and public health agencies are enabling home testing and digital reporting, further increasing compliance and repeat testing rates.
Market Challenges
Colonoscopy, while accurate, carries procedural risks such as perforation, bleeding, infection, and sedation-related complications, limiting its uptake. A 2025 study published by NCBI indicated perforation and bleeding rates of 0.078% and 0.235%, respectively, among adults over 65, with higher risks in those over 80. Awareness of these risks is shifting preference toward non-invasive stool-based and molecular tests, restricting colonoscopy adoption.
Market Trends
The market is witnessing a shift toward less invasive, patient-friendly pathways. Stool-based tests are increasingly used as first-line screening, reserving colonoscopy for confirmation. Technological advancements in colonoscopy, such as high-definition imaging, AI-based polyp detection, and single-use endoscopes, are improving diagnostic yield while addressing infection risks.
By Type:
By End-User:
Competitive Landscape
Prominent players include Olympus Corporation, Exact Sciences Corporation, Quest Diagnostics, FUJIFILM Holdings, and Clinical Genomics Technologies, focusing on advanced colonoscopy and stool-based products. Recent developments include:
Conclusion
The global colorectal cancer screening market is poised for steady growth, fueled by rising CRC incidence, technological innovations, and adoption of non-invasive and home-based screening tests. While colonoscopy remains the gold standard, non-invasive solutions are expanding access, improving compliance, and driving market expansion globally. By 2034, the market is expected to reach USD 27.69 billion, offering significant opportunities for diagnostic companies, healthcare providers, and public health agencies worldwide.
Segmentation By Type, End-user, and Region
By Type * Stool-based
By End-user
Hospitals & Clinics
By Region * North America (By Type, End-user, and Country)